New Innovative Cancer Therapy Study for Subjects with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma

(approved by the FDA, Cancer Therapy Experts and the Ethical Review Board)

Sarcoma is an extremely rare type of cancer, and Alveolar Soft Part Sarcoma (ASPS), Leiomyosarcoma (LMS) and Synovial Sarcoma are even rarer subtypes of this disease. Due to the enigmatic and aggressive nature of these sarcomas, data to assess the efficacy of existing chemotherapy treatments is still on-going. At this time, there is currently no FDA approved treatment for advanced or metastatic ASPS, and there are limited options for chemotherapy regimens used to treat advanced LMS and Synovial Sarcoma.

Malignant tumors often grow and metastasize by creating new blood vessels through which they can siphon oxygen and nutrients from the rest of the body. This FDA approved study compares a standard chemotherapy agent with a new innovative treatment that works to inhibit the cancer's ability to form these new blood vessels, eventually cutting off its oxygen supply and subsequent growth.

This treatment is also expected to prove more attractive to patients due to the fact that it is given orally once daily, rather than over the several hours of IV infusion required for current standard of care chemotherapy administration. Experts believe that this treatment will be better tolerated and result in less toxicity.

For more information, please contact the Sarcoma Oncology Center at (310) 552-9999, or email the office at info@sarcomaoncology.com.

ClinicalTrials.gov Identifier: NCT03016819